1310 patents
Page 3 of 66
Utility
Antiviral Pyrazolopiridinone Compounds
16 Nov 23
Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
Filed: 6 Feb 23
Utility
Compounds and Compositions for Inducing Chondrogenesis
16 Nov 23
Ha-Soon CHOI, Jiqing JIANG, James Paul LAJINESS, Bao NGUYEN, Hank Michael James PETRASSI
Filed: 18 Jul 23
Utility
COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS
16 Nov 23
The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.
Trixi Brandl, Claus Ehrhardt, Robert Epple, Christian Markert, Pascal Rigollier, Juraj Velcicky
Filed: 15 Sep 21
Utility
Natriuretic Peptide Receptor 1 Antibodies and Methods of Use
16 Nov 23
This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
Filed: 30 Mar 23
Utility
Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
14 Nov 23
Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Liansheng Su, Lihua Yang, Rui Zheng
Filed: 12 Mar 21
Utility
Treatment of Autoimmune Disease In a Patient Receiving Additionally a Beta-blocker
9 Nov 23
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
Eric LEGANGNEUX, Alexandros SAGKRIOTIS, Pierre JORDAAN, Florine POLUS, Alan John CAMM, Shibadas BISWAL, Parasar PAL, Uday Kiran VELDANDI, Atul Keshav PAWAR, Vassilios ASLANIS, Kasra SHAKERI-NEJAD
Filed: 14 Jul 23
Utility
Modified Release Formulation
9 Nov 23
Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided.
Bruno GALLI, Jean-Marie GLANTZMANN, Arnaud GRANDEURY, Klaus-Peter MOLL, Martin MUELLER-ZSIGMONDY, Karsten PUTZBACH, Dirk SPICKERMANN, Hubert THOMA, Mike UFER
Filed: 20 Jul 23
Utility
Corrected1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC Acid, (E)-BUT-2-ENEDIOIC Acid
9 Nov 23
This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethy-l-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment.
Lech CISZEWSKI, Marilyn DE LA CRUZ, Piotr H. KARPINSKI, Michael MUTZ, Christian RIEGERT, Caspar VOGEL, Ricardo SCHNEEBERGER
Filed: 10 Aug 22
Utility
Multispecific Antibodies Targeting IL-13 and IL-18
9 Nov 23
Described herein are multispecific antibodies targeting IL-13 and IL-18.
Michael Otto BARDROFF, Regis CEBE, Jiri KOVARIK, Frank KOLBINGER, Michael KIFFE, Anett RITTER, Lukas ROTH
Filed: 25 Apr 23
Utility
Cell Secreted Minibodies and Uses Thereof
9 Nov 23
The present invention relates to compositions and methods for using a minibody.
Laura Alexandra Johnson, Danielle Cook
Filed: 9 Dec 22
Utility
NMDA receptor modulators and uses thereof
7 Nov 23
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder.
David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
Filed: 27 Jan 22
Utility
Selection vectors and methods of selecting eukaryotic host cells
7 Nov 23
The disclosure is directed to an expression vector or a combination of at least two expression vectors for producing a polypeptide of interest, the vector or vectors comprising a polynucleotide encoding a mutated folate receptor as a selectable marker.
Yehuda G Assaraf, Thomas Jostock, Hans-Peter Knopf
Filed: 29 Jul 14
Utility
Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists
2 Nov 23
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
Filed: 2 Dec 22
Utility
Process for the Manufacture of 1,4-DISUBSTITUTED Pyridazine Compounds
2 Nov 23
The invention relates to a novel process, novel process step(s) and novel intermediate(s) useful for the preparation of 1,4-disubstituted pyridazine compounds, such as 5-(1H-Pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol.
Nicolas AMIOT, Darija DEDIC, Peng FU, Fabrice GALLOU, Xingxian GU, Cornelius HARLACHER, Siqian LIU, Shuping YAO, Jiong YE, Jianguang ZHOU
Filed: 24 Jun 21
Utility
Methods and Compositions for Ocular Cell Therapy
2 Nov 23
The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy.
Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O’CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
Filed: 26 Apr 21
Utility
Pharmaceutical products and stable liquid compositions of IL-17 antibodies
31 Oct 23
The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions.
Susanne Joerg, Kathrin Serno-Schersch
Filed: 21 Dec 15
Utility
Methods of treating FGF21-associated disorders
31 Oct 23
The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
Filed: 1 Dec 21
Utility
MDM2 Inhibitors for Use In the Treatment or Prevention of Hematologic Neoplasm Relapse after Hematopoietic Cell Transplantation
26 Oct 23
The invention relates to a mouse double minute 2 (MDM2) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient.
Robert Zeiser, Justus Duyster, Hans Dietrich Menssen
Filed: 21 Sep 21
Utility
Treatment of CLL
26 Oct 23
The present invention relates to anti-BAFFR antibodies or binding fragments thereof, alone or in combination with BTK inhibitors, for use in the treatment of CLL.
Liangke GOU, Nadia HASSOUNAH, Janghee WOO
Filed: 2 Aug 21
Utility
Method of Adjuvant Cancer Treatment
19 Oct 23
The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
Sylvie LAQUERRE, Peter F. LEBOWITZ
Filed: 7 Dec 22